Trisalus Life Sciences (TLSI) Registration Filing summary

Company overview and business model

• Focuses on oncology, integrating innovative delivery technology with standard-of-care therapies and investigational immunotherapeutic nelitolimod for solid tumors.

• Technology addresses high intratumoral pressure and off-target delivery, aiming to improve therapeutic response and patient outcomes.

• Principal executive offices in Westminster, Colorado; incorporated in Delaware.

Financial performance and metrics

• Raised $22.0 million in gross proceeds from a private placement of 5,500,000 shares at $4.00 per share, closed May 2, 2025.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling stockholders; all proceeds go to selling stockholders.

• Company bears registration-related costs; selling stockholders bear commissions and discounts.